Pfizer loses top vaccine scientist Jansen who led drive for COVID-19 shot, searches for successornews2022-04-29T19:23:24+00:00April 29th, 2022|Fierce Pharma|
Novo’s Wegovy supply rebound on track for later this year as demand stays strongnews2022-04-29T17:32:03+00:00April 29th, 2022|Fierce Pharma|
Amid legal tumult, J&J shareholders reject proposal to end talc sales worldwidenews2022-04-29T17:04:51+00:00April 29th, 2022|Fierce Pharma|
Amid Humira’s decline, AbbVie’s Rinvoq falls short of analyst forecasts and Skyrizi deliversnews2022-04-29T15:05:39+00:00April 29th, 2022|Fierce Pharma|
AstraZeneca’s Farxiga hits $1B quarterly mark, but flagship oncology and China units lagnews2022-04-29T14:46:54+00:00April 29th, 2022|Fierce Pharma|
Innovating One of the World’s Most Common Vaccines in Era of Consumer Choicenews2022-04-29T14:37:12+00:00April 29th, 2022|Fierce Pharma|
As superstar Revlimid fades faster than expected, BMS trims $600M from its 2022 sales projectionnews2022-04-29T14:02:10+00:00April 29th, 2022|Fierce Pharma|
Fierce Pharma Asia—Astellas’ gene therapy ding; BeiGene, Novartis’ PD-1 win; Serum Institute’s unused COVID shotsnews2022-04-29T12:53:28+00:00April 29th, 2022|Fierce Pharma|
Biogen CEO’s 2021 pay remains level despite Aduhelm tribulationsnews2022-04-29T12:21:41+00:00April 29th, 2022|Fierce Pharma|
Gilead’s two cents: Drugmaker gets a boost from Biktarvy, Veklury but $2.7B writedown crushes earningsnews2022-04-29T12:03:22+00:00April 29th, 2022|Fierce Pharma|
